Changing Landscape of Diagnosis and Treatment Options for Multiple Myeloma – Enduring Webcast

Description

Program Description

---

Multiple myeloma (MM) develops in the bone marrow, where blood cells are created. Common blood and urine tests, cytogenetics, and genomes are diagnostic. A patient must get all necessary tests to establish disease severity, prognosis, and treatment options. Pivotal studies examined the cytogenetic classification, staging, risk stratification, and novel treatment approach with protease inhibitors (carfilzomib, ixazomib, bortezomib), monoclonal antibodies (datatuzumab, elotuzumab, isatuximab), immunomodulatory agents (lenalidomide), histone deacetylase inhibitors (panobinostat, vorinostat), doublet and triplet combination therapies in newly diagnosed and relapsed/refractory MM (RRMM); and the evolving role of bispecific antibodies (BsAbs), antibody-drug conjugates (ADC) and CAR-modified T-cell therapy for patients with RRMM.

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and nurses

Commercial Supporter

---

This activity is supported by an educational grant from Sanofi.